Aardvark Therapeutics (AARD) Liabilities and Shareholders Equity (2024 - 2026)

Aardvark Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $98.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 37.21% year-over-year to $98.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $496.5 million (up 111.69% YoY) and the FY2025 annual result came in at $117.2 million, up 51.19% from the prior year.
• Liabilities and Shareholders Equity eased to $98.6 million in Q1 2026 per AARD's latest filing, from $117.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $157.0 million in Q1 2025 and troughed at $77.5 million in Q4 2024.
• A 3-year average of $121.8 million and a median of $125.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity surged 51.19% in 2025, then tumbled 37.21% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $77.5 million in 2024, then soared by 51.19% to $117.2 million in 2025, then declined by 15.87% to $98.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $98.6 million, $117.2 million, and $133.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.